US Patent Issued to THRYV THERAPEUTICS on Sept. 22 for "Pyrazolo[3,4-dpyrimidin-6-yl-sulfonamide derivatives for the inhibition of SGK-1" (Canadian, American Inventors)

ALEXANDRIA, Va., Sept. 24 -- United States Patent no. 12,741,970, issued on Sept. 22, was assigned to THRYV THERAPEUTICS INC. (Montreal).

"Pyrazolo[3,4-dpyrimidin-6-yl-sulfonamide derivatives for the inhibition of SGK-1" was invented by Marc Vidal (Laval, Canada), Maroua Khalifa (Laval, Canada) and Martin Maguire (Plattsburgh, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compounds of Formula I: Formula I and pharmaceutically acceptable salts thereof are provided for as inhibitors of SGK-1 for example for the treatment of conditions such as Long QT syndrome, heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, ste...